| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T83797 | ||||
| Target Name | Hepatocyte growth factor | ||||
| Target Type | Clinical Trial |
||||
| Action against Disease Model | Rilotumumab | Enhances temozolomide- and docetaxel-induced anti-proliferative effects in U87-MG cells in vitro; Increases docetaxel-induced apoptosis in U87-MG in vitro;Enhances temozolomide-and docetaxel-induced anti-growth effects in U87-MG xenografts | [529502] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | c-Met conditional knockout mice treated with N-nitrosodiethylamine developed significantly more and bigger t uMors and with a shorter latency compared with control mice | [529502] | |||
| References | |||||
| Ref 529502 | Nat Rev Drug Discov. 2008 Jun;7(6):504-16.Drug development of MET inhibitors: targeting oncogene addiction and expedience. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.